ClinicalTrials.gg
RecruitingNCT06044623IMPORTANTUpdated Nov 19, 2024

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

A Phase 3 interventional study of CDK 4/6 inhibitors and Endocrine therapy in Metastatic Breast Cancer, Advanced Breast Cancer and Quality of Life, sponsored by Region Örebro County. Recruiting at 12 sites in 6 countries. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by Region Örebro County · Phase 3, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
495
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 186 studies in Breast Neoplasms with a site in Greece — 30 open to participants now, 65 under way, 39 of them phase 3. Breast Neoplasms · Greece.

Planned enrollment
71st of 152
495 · median 467
Started
2024
with 8 others
Phase 3
90 of 186
14 open now
Primary completion
2028-10
later than 48 of 64 live
Registered
153rd of 186
by date

Among the 186 studies in Breast Neoplasms with a site in Greece, this one is the 71st largest by planned enrollment of the 152 interventional ones that give a count, is one of 9 that started in 2024, is one of 90 in phase 3, reaches primary completion later than 48 of the 64 other live ones, and was the 153rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

30 of the 186 studies in Breast Neoplasms with a site in Greece are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Breast Neoplasms with a site in Greece, or all of them as a file.
02

Study summary

IMPORTANT study is a multicenter, open-label, prospective, randomized-controlled, non-inferiority trial with a pragmatic approach involving older patients (≥ 70 years old) with advanced hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, not amenable for curative treatment and without prior therapy for advanced disease, who are suitable to receive CDK 4/6-inhibitors plus endocrine therapy as first line therapy. The study implements two approaches with high level of evidence, namely the use of comprehensive geriatric assessment (CGA) approach in treatment decision making and the use of CDK 4/6-inhibitors as the initial treatment of choice, to investigate whether a common clinical practice (starting dose reduction of CDK 4/6-inhibitors in older patients) with evidence of low certainty can be standardized using a more individualized-based approach.

On the basis of baseline CGA assessment, patients will either receive full dose of CDK 4/6-inhibitors plus endocrine therapy (if patients are fit according to CGA) or be randomized to full dose vs. reduced initial dose of CDK 4/6-inhibitors (if vulnerable or frail according to CGA). The study hypothesis is that adjusting the dose according to vulnerability will allow patients to tolerate treatment better without jeopardizing the treatment efficacy.

This project has received funding from the European Union's HORIZON 2022 research and innovation actions supporting the implementation of the Mission on Cancer under grant agreement No 101104589.

03

Conditions studied

  • Metastatic Breast Cancer
  • Advanced Breast Cancer
  • Quality of Life
  • Toxicity
  • Older Patients

Browse trials for

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following inclusion criteria will be applied:

  1. Patients male or female aged at least 70 years old at the time of .
  2. or cytologically confirmed diagnosis of HR-positive (defined as estrogen-receptor ≥ 1%), -negative breast cancer according to analysis of the most recent tumor specimen by local laboratory.
  3. Advanced (locoregionally recurrent or ) breast cancer not amenable to curative treatment.
  4. No prior systemic treatment for advanced disease (recurrence during neo-/ endocrine therapy is allowed). A prior period of treatment with aromatase inhibitors or fulvestrant for up to 28 days from the CDK 4/6-inhibitor initiation is allowed.
  5. Adjuvant treatment with CDK 4/6-inhibitors is allowed provided a disease-free interval from treatment end >12 months.
  6. Either or non-measurable bone only disease, but evaluable according to criteria 1.1.
  7. Written informed consent prior to any study-specific procedures.
  8. Adequate organ function as defined in the summary of product characteristics (SmPC) for the CDK 4/6-inhibitors that is planned to be used.
  9. Able to swallow capsules.
  10. Able to understand and consent in English language or in native language for each participating country.

Exclusion criteria

Exclusion Criteria:

Eligible patients will be excluded if they have one of the following criteria:

  1. Patients considered from treating physician as non-suitable for treatment with CDK 4/6-inhibitors.
  2. according to SmPC for the CDK 4/6-inhibitors that is planned to be used.
  3. Presence of visceral crisis, lymphangitis carcinomatosis, or .
  4. History of any other cancer (except of non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years.
  5. Participating in other interventional trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
495 participants (estimated)

Study arms

  • Experimental
    Lower initial dose of CDK 4/6-inhibitor (vulnerable/frail patient cohort)

    -1 level dose reduction as initial dose of either one of the CDK 4/6-inhibitors: Palbociclib 100 mg x 1 for 21 days with 7 days off; or Ribociclib 400 mg x 1 for 21 days with 7 days off; or Abemaciclib 100 mg x 2 daily added to endocrine therapy.

    Drug: CDK 4/6 inhibitors · Drug: Endocrine therapy

  • Active comparator
    Full initial dose of CDK 4/6-inhibitor (vulnerable/frail patient cohort)

    Full initial dose of either one of the CDK 4/6-inhibitors: Palbociclib 125 mg x 1 for 21 days with 7 days off; or Ribociclib 600 mg x 1 for 21 days with 7 days off; or Abemaciclib 150 mg x 2 daily) added to physician's choice endocrine therapy.

    Drug: CDK 4/6 inhibitors · Drug: Endocrine therapy

  • Other
    Full initial dose of CDK 4/6-inhibitor (fit patient cohort)

    Full initial dose of either one of the CDK 4/6-inhibitors: Palbociclib 125 mg x 1 for 21 days with 7 days off; or Ribociclib 600 mg x 1 for 21 days with 7 days off; or Abemaciclib 150 mg x 2 daily) added to physician's choice endocrine therapy.

    Drug: CDK 4/6 inhibitors · Drug: Endocrine therapy

Interventions

  • DrugCDK 4/6 inhibitors

    Either Palbociclib, Ribociclib or Abemaciclib

  • DrugEndocrine therapy

    Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor

This study also gives PalbociclibStudies of PalbociclibPalbociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., FulvestrantStudies of FulvestrantFulvestrant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Time to treatment failure

    The time from randomization to treatment discontinuation because of any reason including disease progression, treatment toxicity, or death due to any cause.

    Time frame: Up to 5 years from treatment initiation

Secondary outcomes

  1. Overall treatment utility (OTU)

    A composite endpoint that will be assessed at the first efficacy evaluation. OTU incorporates objective and participant-reported outcome measures of anticancer efficacy, tolerability and acceptability of treatment providing a simple "good, intermediate or poor" categorization of outcome.

    Time frame: Three months after treatment initiation

  2. Overall survival

    The time from randomization to death from any cause.

    Time frame: Up to 5 years from treatment initiation

  3. Progression free survival

    The time from randomization to first documented evidence of disease progression or death from any cause.

    Time frame: Up to 5 years from treatment initiation

  4. Time to chemotherapy initiation

    The time from randomization until the initiation of chemotherapy at any treatment line after CDK 4/6-inhibitors.

    Time frame: Up to 5 years from treatment initiation

  5. Frequency of adverse events

    Adverse events will be assessed based on adverse events, as graded by CTCAE v 5.0 before each cycle and up to 28 days after the end of CDK 4/6-inhibitors.

    Time frame: Up to 5 years from treatment initiation

  6. Assessment of Quality of life

    Quality of life will be assessed using three validated questionnaires, EORTC Quality of Life Questionnaire (QLQ)-C30, Elderly (ELD)-14, and European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L).

    Time frame: Until disease progression, participant / physician decision to stop, death, or up to 24 months from treatment initiation whichever occurs first

  7. Time until Quality of life deterioration

    QoL deterioration, defined as the time from randomization until any clinically meaningful worsening (using minimal important differences as cut-off) of any QoL aspect measured by the questionnaires.

    Time frame: Until disease progression, participant / physician decision to stop, death, or up to 24 months from treatment initiation whichever occurs first

  8. Cost effectiveness

    Resource use, length of life and quality of life data will be collected during the trial for the purpose of conducting an economic evaluation.

    Time frame: Up to 24 months from treatment initiation

07

Study locations

2 of 12 sites recruiting
  • Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki
    Helsinki, Finland
    Recruiting
  • Fourth Oncology Department & Comprehensive Clinical Trials Center, Metropolitan Hospital
    Athens, Greece
    Not yet recruiting
  • Second Department of Medical Oncology, Hygeia Hospital
    Athens, Greece
    Not yet recruiting
  • Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School
    Patras, Greece
    Not yet recruiting
  • Medical Oncology Unit, S. Andrew Hospital
    Patras, Greece
    Not yet recruiting
  • Second Department of Medical Oncology, Euromedica General Clinic
    Thessaloníki, Greece
    Not yet recruiting
  • Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi
    Florence, Italy
    Not yet recruiting
  • "Sandro Pitigliani" Department of Medical Oncology, Hospital of Prato
    Prato, Italy
    Not yet recruiting
  • Department of Oncology, Akershus University Hospital (AHUS)
    Oslo, Norway
    Not yet recruiting
  • Department of Medical Oncology, Hospital Clinic of Barcelona
    Barcelona, Spain
    Not yet recruiting
  • Department of Oncology, Uppsala University Hospital
    Uppsala, 75185, Sweden
    Not yet recruiting
  • Department of Oncology, Örebro University Hospital
    Örebro, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Oct 2028, 54 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 54 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2023
First posted
Sep 21, 2023
StartActual
Apr 1, 2024
Primary completionEst.
Oct 31, 2028
CompletionEst.
May 31, 2029
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06044623
Collaborators
University of Patras, University of Florence, Azienda USL Toscana Centro, Helsinki University Central Hospital, Institute for Medical Technology Assessment - the Netherlands, Security Labs Consulting Limited, Circular Economy Foundation, Universidad Nacional de Educación a Distancia, Hellenic Cooperative Oncology Group, University Hospital, Akershus, Uppsala County Council, Sweden, Hospital Clinic of Barcelona, Phaze Clinical Research & Pharma Consulting, Bröstcancerförbundet, Eunomia Ltd, University of Applied Sciences and Arts Northwestern Switzerland, CareAcross, Örebro University, Sweden
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Apr 1, 2024
Primary completion
Oct 31, 2028 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Nov 19, 2024

Study contacts

Antonios Valachis, Assoc Prof
Contact
important@oru.se
+46196021792
Antonios Valachis, Assoc Prof
study chair · Region Örebro Län

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Palbociclib · Ribociclib

Start the discussion